Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Impact · against what's priced in

Artelo Biosciences (ARTL) receives a positive catalyst through a USPTO Notice of Allowance extending IP protection for ART27.13 through 2041 and strong interim CAReS data. The upcoming Q4 results from the DREAM study provide a secondary near-term valuation driver.

ARTL+0.70: No priced-in read yet

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

What matters in this story

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

What matters in this story

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

How each ticker is affected

Connected tickers

Track these names every morning.

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

MannKind Q3 Earnings Call Highlights

Windward Bio Group Shows Enticing Lead Drug Trial Results On Eve Of IPO

AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

What matters in this story

Next reads from the same story arc

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

What matters in this story

Next reads from the same story arc

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

How each ticker is affected

Connected tickers

Track these names every morning.

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

MannKind Q3 Earnings Call Highlights

Windward Bio Group Shows Enticing Lead Drug Trial Results On Eve Of IPO

AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy